DKK1, a negative regulator of Wnt signaling, is a target of the β-catenin/TCF pathway

Overview of attention for article published in Oncogene, September 2004

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (86th percentile)
High Attention Score compared to outputs of the same age and source (84th percentile)

Mentioned by

patent: 10 patents

Citations

dimensions_citation: 475 Dimensions

Readers on

mendeley: 285 Mendeley

Summary Patents Dimensions citations

So far, Altmetric has seen 10 patents that reference this research output.

Anti-sclerostin antibodies and their use to treat bone disorders as part of a regimen

Grant US-11851483-B2

United States of America

Treatment of cardiovascular disease using ActRII ligand traps

Grant US-11813308-B2

United States of America

Genetic markers for engraftment of human cardiac ventricular progenitor cells

Grant US-11725244-B2

United States of America

Methods for isolating human cardiac ventricular progenitor cells

Grant US-11401508-B2

United States of America

Use of beta-catenin as a biomarker for treating cancers using anti-dkk-1 antibody

Grant US-11267876-B2

United States of America

PEPTIDE DERIVED FROM DKK-1 HAVING WHITENING ACTIVITY DERIVED FROM NEURAL STEM CELL…

Application KR-102352313-B1

Republic of Korea

Use of Neuropilin-1 (NRP1) as a cell surface marker for isolating human cardiac…

Grant US-11186820-B2

United States of America

Anti-LRP6 antibodies

Grant US-9556267-B2

United States of America

Anti-LRP6 antibodies

Grant US-8846041-B2

United States of America

USE OF ANTI-DKK1 MONOCLONAL ANTIBODY FOR TREATMENT OF LIVER CANCER

Application WO-2012103787-A1

World Intellectual Property Organisation (WIPO)